Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety
CADTH
Record ID 32015000293
English
Authors' recommendations:
No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/sep-2014/RB0672%20DAA%20treatment%20failure%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antiviral Agents
- Hepatitis C
- Sofosbuvir
- Simeprevir
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.